NCT04651634 2025-04-06
MIT-001
MitoImmune Therapeutics
Phase 2 Active not recruiting
Clinical Trials
28 trialsNCT05966194 2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2 Recruiting
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT05493800 2024-05-29
Capella
MitoImmune Therapeutics
Phase 2 Active not recruiting
NCT03200340 2023-07-27
EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation
Enzychem Lifesciences Corporation
Phase 2 Completed
NCT02229136 2022-12-01
Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
US Oncology Research
Phase 2 Completed
NCT04529850 2022-08-16
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
Galera Therapeutics, Inc.
Phase 2 Completed
NCT02399228 2021-11-19
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis
Santalis Pharmaceuticals, Inc.
Phase 2 Completed
NCT02508389 2021-09-20
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
Galera Therapeutics, Inc.
Phase 2 Completed
NCT01403064 2021-05-11
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
CSL Behring
Phase 2 Terminated
NCT03234465 2020-11-23
Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day
Oragenics, Inc.
Phase 2 Terminated
NCT02542215 2019-12-02
Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy
Mallinckrodt
Phase 2 Terminated
NCT02606994 2019-02-06
TPvsM
Oral Defense, LLC
Phase 2 Terminated
NCT02324335 2019-01-16
Brilacidin
Innovation Pharmaceuticals, Inc.
Phase 2 Completed
NCT02885376 2018-12-21
Study of Dentoxol® Mouthrinse for Oral Mucositis
Ingalfarma SpA
Phase 2 Completed
NCT03577535 2018-08-01
Evaluation of ONCOXIN® in Oral Mucositis, Appetite and Body Mass in Cancer Patients.
Catalysis SL
Phase 2 Completed
NCT01400620 2018-03-13
Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer
Izun Pharma Ltd
Phase 2 Completed
NCT01385748 2017-11-28
Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis
Valerio Therapeutics
Phase 2 Completed
NCT02013050 2017-08-28
A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
Soligenix
Phase 2 Completed
NCT00323518 2016-04-13
A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis
Celldex Therapeutics
Phase 2 Completed
NCT00104065 2016-03-15
Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant
Celldex Therapeutics
Phase 2 Completed
NCT00189488 2014-09-15
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
Swedish Orphan Biovitrum
Phase 2 Completed
NCT01247246 2014-05-26
Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer
SciClone Pharmaceuticals
Phase 2 Unknown
NCT01083875 2010-03-18
Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region
Access Pharmaceuticals, Inc.
Phase 2 Completed
NCT00756951 2009-11-23
SCV-07 OM
SciClone Pharmaceuticals
Phase 2 Completed
NCT00385515 2009-05-07
Efficacy of SNX-1012 in the Treatment of Oral Mucositis
Mucosal Therapeutics
Phase 2 Completed
NCT00289003 2007-01-17
The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients
Biotec Pharmacon ASA
Phase 2 Completed
NCT00230191 2007-01-15
Safety and Efficacy of RK0202 in Oral Mucositis
RxKinetix
Phase 2 Completed